Human Vaccines - Global Market Opportunities

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.MARKET OVERVIEW & OUTLOOK
Market Dynamics
Global Human Vaccine Market: A Snapshot
Vaccine Pricing: The Developed – Developing Divide
Looking Ahead
Key Markets
Competitive Scenario
World’s Leading Producers
ALK- The Global Leader in Allergy Vaccines
3.PRODUCT FACTS
Prophylactic Vaccines
Therapeutic Vaccines
Prophylactic Pediatric Vaccines
A Mature Market
Prophylactic Adult Vaccines
Favorable Market Growth
4.MARKET TRENDS & ISSUES
Newer Vaccines in Pipeline to Cheer Up Pharma Companies
Threat of Pandemic Rejuvenates Vaccine Market
Influenza Vaccines on a Growing Spree
Influenza Market Faces Several Challenges
Economic Factors Hamper Optimal Vaccine Development and Delivery
Increasing Need for Vaccine Promotion in the Developing Regions
Changing Vaccine Needs
DNA Vaccines: Engineering Growth
AIDS Vaccine: Long Road Ahead
Noninjectable Vaccines: Gain Without Pain
Need for a Human Vaccine for Leishmaniasis
Conjugate Vaccines: A Technological Innovation
Need For a New TB Vaccine
Companies Involved in TB Vaccine Research
Religious Concerns Over Immunizing Young Girls
Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
DTaP Vaccines Approved for Booster Vaccination
Advances in Biotechnology Spearheading Vaccines’ Growth
BioWarfare: Threat Perception and Preparedness
Overview of Potential Bio-Terrorist Agents
Smallpox (Variola Major)
Anthrax (Bacillus Anthracis)
Plague (Yersinia Pestis)
Botulism (Clostridium Botulinum)
Tularemia (Francisella Tularensis)
Market Concerns
Safety Factor
Development Delays
Storage Problems
Perfluorocarbons as Alternative to Overcome Storage Problems
Costs
Standards for Vaccine Safety and Quality
5.DISTRIBUTION CHANNELS
6.TECHNOLOGICAL DEVELOPMENTS
Applying Gene Therapy to Develop Therapeutic Solutions
Research and Trials of AIDS Vaccines
Ongoing R&D for AIDS Vaccines
International AIDS Vaccine Initiative (IAVI)
Cancer
Cancer Type and Area Effected
Immunotherapies for Cancer
Drugs for Cancer
Issues Effecting the Development of Commercially Viable Cancer Vaccines
Frequency of Vaccination
Growth Boosters in the Cancer Vaccines Market
Cancer Vaccines Available
Select Cancer Vaccines in Trial Stage
Other Vaccines for Cancer
Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
7.CORPORATE DEVELOPMENTS
Intercell Partners SSI and Sanofi Pasteur to Further Develop TB Vaccine
GSK Receives US FDA Approval for ROTARIX® Rotavirus Vaccine
Dynavax and Merck & Co Announce Clinical Hold of HEPLISAV Vaccine Trial
Crucell Enters into Exclusive Development Agreement with Wyeth Pharmaceuticals
Crucell and Sanofi Ink an Agreement for Advanced Anti-Rabies Biologicals
FDA Confers Priority Designation for Supplemental Application for GARDASIL ®
Sanofi Submits a European Marketing Approval Application for First Influenza Vaccine
Bavarian Nordic’s IMVAMUNE® Post- Exposure Vaccination Demonstrates Protection Against Fatal Poxvirus Infection
BSU Scientists to Commence Human West Nile Vaccine Development Project
Intercell Concludes First Phase Clinical Studies of IC31® Adjuvanted Influenza Vaccine
GlaxoSmithKline Acquires Reliant Pharmaceuticals
GSK Acquires Praecis Pharmaceuticals
Berna Biotech Divests Stake in Pevion Biotech
Crucell Inks a Research License Agreement with ISU ABXIS of Korea
Crucell and Acambis Ink a Licensing Agreement for PER.C6 ® Technology
Novartis and Intercell Join Hands to Advance Vaccine Programs
Merck Plans to Establish a Human Vaccine Facility in Ireland
Dynavax and Merck to Enter into Partnership to Develop Hepatitis B Vaccine
Maxygen and Sanofi Pasteur Sign License Agreement
Novartis Wins US Government Contract for Developing Antigen Technology
MedImmune Announces Licensing of Reverse Genetics Technology to GlaxoSmithKline
MedImmune Wins US Government Contract
MedImmune and Human Genome Sciences Sign Lease Agreement
Acambis Announces Signing of Collaboration Agreement with Sanofi Pasteur
Acambis Announces JE Partnership Agreement with Sanofi Pasteur
Crucell Procures Major Patent for Influenza Vaccine Production
CSL Receives FDA Approval for Influenza Virus Vaccine
GlaxoSmithKline Inks Contract with UK Government
Merck & Co., Inc. and Dynavax to Jointly Develop Hepatitis B Vaccine
Sanofi Pasteur Wins Contract to Design, Retrofit and Maintain Influenza Vaccine Unit
Sanofi Pasteur Completes Construction of Influenza Vaccine Production Unit
GlaxoSmithKline to Introduce Five Key Medicines for Oncology
FFF Enterprises Unveils My Flu Vaccine Network
CSL Biotherapies Files BLA for Influenza Vaccine
Acambis Pioneers Testing of West Nile Virus Vaccine in Grown Ups
Acambis Initiates Test of single-dose JE vaccine in India
Sanofi Pasteur Begins Phase 2 Testing of New Influenza Vaccine
8.MAJOR PLAYERS
ALK – Abelló A/S (Denmark)
Acambis PLC (UK)
Bavarian Nordic A/S (Denmark)
Crucell N.V. (The Netherlands)
CSL Ltd. (Australia)
GlaxoSmithKline PLC (UK)
GlaxoSmithKline Biologicals S.A (Belgium)
MedImmune, Inc. (USA)
Merck & Company, Inc. (USA)
Novartis Vaccines & Diagnostics, Inc. (USA)
Sanofi-Aventis S A (France)
Sanofi Pasteur SA (France)
Sanofi Pasteur Inc. (USA)
Shantha Biotechnics Ltd. (India)
Vaxin, Inc. (USA)
Wyeth (USA)
9.GLOBAL MARKET ANALYTICS
10.THE UNITED STATES
Market Constraints
Supply Shortages
Pediatric Vaccines Market
Market Focus Shifting from Pediatric Vaccines
Growth Boosting Factors for US Pediatric Vaccines Market
Demand Restraining Factors for US Pediatric Vaccines Market
‘Bright’ Outlook for Therapeutic Vaccines
Market Share of Key Players in North America
The US Influenza Vaccine Market
Problems Effecting Timely Supply of Influenza Vaccine
Need for Immunization Schedule for Adults
Federal Research & Grants
National Cancer Institute
National Institutes of Health (NIH)
NIH Scientists Showcase Potential West Nile Virus Vaccine
NIH Doles Out Grants to Biotech Companies
The National Institute of Allergy and Infectious Diseases (NIAID)
Intramural Research
Extramural Divisions
Vaccine Pricing in the US
Regulatory Environment
Review Process Make Vaccines Safer
11.CANADA
12.JAPAN
13.EUROPE
a. France
b.Germany
c.Italy
d.The United Kingdom
e. Spain
f.Russia
g.Rest of Europe
14.ASIA-PACIFIC
Asian Vaccine Industry
Challenges
China
State Drug Administration: Regulatory Authority in China
India
Development Pipeline
Hepatitis B Vaccine in India
Panacea Biotec: A Leading Manufacturer of Hepatitis B Vaccine
Combination Vaccines
International Players Entering the Arena
Heading Towards Greener Pastures
The Patent Act (Third Amendment), 2005
15.LATIN AMERICA
Need for an effective TB Vaccine in Brazil
16.REST OF WORLD
Exhibits
Table 1: Percentage Breakdown of Leading Players in the Worldwide Human Vaccines Market): by Value Sales –
Table 2: Percentage Breakdown of Leading Players in the Worldwide Allergy Vaccines Market by Value Sales –
Table 3: Global Human Vaccines Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 4: Percentage Breakdown of Global Human Vaccines Market by Region for the Years 2008 & 2009
Table 5: Global Prophylactic Vaccines Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 6: Percentage Breakdown of Global Prophylactic Vaccines Market by Region for the Years 2008 & 2009
Table 7: Global Prophylactic Vaccines Market by Product Segment for the Period 2007-2015 (Sales in US$ Million)
Table 8: Percentage Breakdown of Global Prophylactic Vaccines Market by Product Segment for the Years 2008 & 2009
Table 9: Global Pediatric Prophylactic Vaccines Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 10: Percentage Breakdown of Global Pediatric Prophylactic Vaccines Market by Region for the Years 2008 & 2009
Table 11: Global Adult Prophylactic Vaccines Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 12: Percentage Breakdown of Global Adult Prophylactic Vaccines Market by Region for the Years 2008 & 2009
Table 13: Global Therapeutic Vaccines Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 14: Percentage Breakdown of Global Therapeutic Vaccines Market by Region for the Years 2008 & 2009
Table 15: Percentage Breakdown of Leading Players in the North American Human Vaccines Market by Value Sales –
Table 16: Percentage Breakdown of Influenza Vaccines Market in the US by Value Sales –
Table 17: Human Vaccines Market by Product Group/Segment in the US: 2007-2015 (Sales in US$ Million)
Table 18: Percentage Breakdown of Human Vaccines Market by Product Segment in the US for the Years 2008 & 2009
Table 19: Human Vaccines Market by Product Group/Segment in Canada: 2007-2015 (Sales in US$ Million)
Table 20: Percentage Breakdown of Human Vaccines Market by Product Segment in Canada for the Years 2008 & 2009
Table 21: Human Vaccines Market by Product Group/Segment in Japan: 2007-2015 (Sales in US$ Million)
Table 22: Percentage Breakdown of Human Vaccines Market by Product Segment in Japan for the Years 2008 & 2009
Table 23: Percentage Breakdown of Leading Players in the European Human Vaccines Market by Value Sales –
Table 24: Percentage Breakdown of Influenza Vaccines Market in Europe by Value Sales –
Table 25: Human Vaccines Market by Country in Europe: 2007-2015 (Sales in US$ Million)
Table 26: Percentage Breakdown of Human Vaccines Market by Region in Europe for the Years 2008 & 2009
Table 27: Human Vaccines Market by Product Group/Segment in Europe: 2007-2015 (Sales in US$ Million)
Table 28: Percentage Breakdown of Human Vaccines Market by Product Segment in Europe for the Years 2008 & 2009
Table 29: Human Vaccines Market by Product Group/Segment in France: 2007-2015 (Sales in US$ Million)
Table 30: Percentage Breakdown of Human Vaccines Market by Product Segment in France for the Years 2008 & 2009
Table 31: Human Vaccines Market by Product Segment in Germany: 2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of Human Vaccines Market by Product Segment in Germany for the Years 2008 & 2009
Table 33: Human Vaccines Market by Product Group/Segment in Italy: 2007-2015 (Sales in US$ Million)
Table 34: Percentage Breakdown of Human Vaccines Market by Product Segment in Italy for the Years 2008 & 2009
Table 35: Human Vaccines Market by Product Group/Segment in the UK: 2007-2015 (Sales in US$ Million)
Table 36: Percentage Breakdown of Human Vaccines Market by Product Segment in the UK for the Years 2008 & 2009
Table 37: Human Vaccines Market by Product Group/Segment in Spain: 2007-2015 (Sales in US$ Million)
Table 38: Percentage Breakdown of Human Vaccines Market by Product Segment in Spain for the Years 2008 & 2009
Table 39: Human Vaccines Market by Product Group/Segment in Russia: 2007-2015 (Sales in US$ Million)
Table 40: Percentage Breakdown of Human Vaccines Market by Product Segment in Russia for the Years 2008 & 2009
Table 41: Human Vaccines Market by Product Group/Segment in Rest of Europe: 2007-2015 (Sales in US$ Million)
Table 42: Percentage Breakdown of Human Vaccines Market by Product Segment in Rest of Europe for the Years 2008 & 2009
Table 43: Human Vaccines Market by Product Group/Segment in Asia-Pacific: 2007-2015 (Sales in US$ Million)
Table 44: Percentage Breakdown of Human Vaccines Market by Product Segment in Asia-Pacific for the Years 2008 & 2009
Table 45: Human Vaccines Market by Product Group/Segment in Latin America: 2007-2015 (Sales in US$ Million)
Table 46: Percentage Breakdown of Human Vaccines Market by Product Segment in Latin America for the Years 2008 & 2009
Table 47: Human Vaccines Market by Product Group/Segment in Rest of World: 2007-2015 (Sales in US$ Million)
Table 48: Percentage Breakdown of Human Vaccines Market by Product Segment in Rest of World for the Years 2008 & 2009
Companies Profiled